Search results
...Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual...
Benzinga· 16 hours agoThe KOL event, "Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the ...
ASLAN expands research on atopic dermatitis treatment By Investing.com
Investing.com· 5 days agoASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage biopharmaceutical company, has announced a new...
Q1 2024 Corvus Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 17 hours agoSecond, our placebo-controlled Phase 1 trial of so-called fitness for patients with moderate to severe atopic dermatitis. We began patient enrollment in ...
Earnings call: Corvus Pharmaceuticals Q1 2024 financial results and trials update By Investing.com
Investing.com· 10 hours agoCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has disclosed its financial outcomes for the first...
Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcri
Guru Focus· 20 hours agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. Corvus Pharmaceuticals Inc (CRVS, Financial) reported a reduced net loss in Q1 2024 of $5.7 ...
Here’s What Getting a Skin Patch Test Is Really Like
Self via Yahoo News· 11 hours agoAccording to Dr. Silverman, this analysis is a great way to “identify triggers for inflamed rashes caused by eczema.” The most common form of this...
Incyte Corp (INCY) Q1 2024 Earnings Call Transcript Highlights: Strategic Acquisitions and ...
GuruFocus.com via Yahoo Finance· 7 days agoExplore key financial outcomes and strategic directions from Incyte Corp's first quarter of 2024, including significant acquisition and revenue details.
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
InvestorPlace· 9 hours agoInvestors concerned about broader market undulations may want to consider the resilience narrative...
Regeneron’s stock rallies as pipeline prospects outweigh earnings miss
Market Watch· 6 days agoThe revenue shortfall was partly due to a decline in sales of the company’s blockbuster eye drug...
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 days agoIncyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript April 30, 2024 Incyte Corporation...
